Current Topics in Medicinal Chemistry,
Год журнала:
2023,
Номер
23(27), С. 2552 - 2589
Опубликована: Авг. 25, 2023
Vaccines
are
instrumental
tools
to
fight
against
novel
and
re-emerging
pathogens
curb
pandemics.
Vaccination
has
been
an
integral
part
of
the
multifaceted
public
health
response
COVID-19
pandemic.
Diverse
vaccine
platforms
have
designed
currently
at
different
stages
development.
Some
vaccines
still
in
early
biological
testing,
while
others
launched
after
being
approved
by
regulatory
agencies
worldwide.
Genomic
that
deliver
parts
viral
DNA
or
RNA
host
cells
gained
popularity
recently
due
their
high
efficiency
fast
manufacture.
Furthermore,
recent
clinical
studies
encouraged
use
within
primary
vaccination
course
enhance
efficacy
vaccination.
Herein,
we
discuss
genomic
vaccines,
which
genetic
material
through
diverse
biotechnology
platforms,
including
vector
messenger
nucleic
acid
vaccines.
We
compare
contrast
characteristics,
composition,
pros
cons
among
as
well
non-genomic
This
review
summarizes
all
current
knowledge
about
could
be
highly
valuable
researchers
interested
ACS Omega,
Год журнала:
2024,
Номер
9(33), С. 35703 - 35717
Опубликована: Авг. 9, 2024
Colorectal
cancer
(CRC)
remains
a
significant
health
burden
globally,
necessitating
deeper
understanding
of
its
molecular
intricacies
for
effective
therapeutic
interventions.
Elevated
monoamine
oxidase-A
(MAO-A)
expression
has
been
consistently
observed
in
CRC
tissues,
correlating
with
advanced
disease
stages
and
poorer
prognosis.
This
research
explores
the
systems
biology
effects
MAO-A
inhibition
small
molecule
inhibitor
clorgyline
regarding
CRC.
The
applied
approach
starts
chemocentric
informatics
to
derive
high-confidence
hypotheses
antiproliferative
inhibitors
ends
experimental
validation.
Our
computational
results
emphasized
anticancer
chemogenomics
similarities
between
structurally
diverse
groups
apoptosis
inducers
addition
highlighting
apoptotic,
DNA-damage,
microRNAs
pathways.
Experimental
validation
revealed
that
MAO
antimigratory
activities
synergistic
doxorubicin.
Moreover,
demonstrated
putative
role
commencing
cellular
death
by
potentially
mediating
induction
apoptosis.
Frontiers in Medicine,
Год журнала:
2023,
Номер
10
Опубликована: Окт. 6, 2023
Background
COVID-19
vaccines
continue
to
save
people’s
lives
around
the
world;
however,
some
vaccine
adverse
events
have
been
a
major
concern
which
slowed
down
vaccination
campaigns.
Anecdotal
evidence
pointed
effect
on
menstruation
but
from
event
reporting
systems
and
biomedical
literature
was
lacking.
This
study
aimed
investigate
physiological
changes
in
women
during
amid
vaccination.
Methods
A
cross-sectional
online
survey
distributed
vaccinated
Nov
2021
Jan
2022.
The
results
were
analyzed
using
SPSS
software.
Results
Among
564
women,
52%
experienced
significant
menstrual
irregularities
post-vaccination
compared
before
regardless
of
type.
kind
irregularity
varied
among
for
example,
33%
had
earlier
menstruation,
while
35%
reported
delayed
menstruation.
About
31%
heavier
whereas
24%
lighter
flow.
29%
last
longer,
13%
it
shorter
than
usual.
Noteworthy,
more
frequent
after
second
shot,
they
disappeared
within
3
months
average.
Interestingly,
these
their
gynecologist.
Conclusion
may
cause
disturbances
Luckily,
short-termed
should
not
be
reason
hesitancy
women.
Further
studies
are
encouraged
unravel
women’s
health.
Abstract
Previous
studies
indicate
an
increased
carditis
risk
among
adolescents
following
the
two-dose
messenger
RNA
COVID-19
vaccine.
Several
jurisdictions
have
extended
interdose
interval
between
first
and
second
doses
to
reduce
risk.
However,
effectiveness
of
such
extension
policy
remains
inconclusive.
Using
territory-wide
vaccine
record-linked
electronic
health
records
in
Hong
Kong,
we
conducted
a
nested
case–control
study
from
February
23,
2021
August
15,
2022.
Adolescents
aged
12
17
who
received
BNT162b2
were
included
for
comparing
risks
standard
(21–27
days)
versus
(
≥
56
days).
The
cumulative
incidence
within
28
days
dose
was
calculated.
adjusted
odds
ratio
estimated
multivariable
conditional
logistic
regression.
We
identified
49
with
newly
diagnosed
dose.
crude
is
37.41
[95%
confidence
(CI):
27.68–49.46]
per
million
vaccinated
adolescents.
Compared
group,
had
significantly
lower
[adjusted
(aOR)
0.34
(95%
CI:
0.16–0.73)].
Sensitivity
analysis
occurring
14
yielded
similar
estimate
[aOR
0.30
0.13–0.73)].
Extending
21
27
or
longer
associated
66%
incident
Our
findings
contribute
towards
evidence-based
vaccination
strategy
vulnerable
population
potentially
informs
product
label
updates.
Introduction
Microsatellite
instable
(deficient
mismatch
repair,
dMMR)
colon
cancer
is
associated
with
hypermutability
and
immune
infiltration-activation.
COVID-19
vaccines
stimulate
immune-inflammation
response.
This
study
aimed
to
investigate
the
types
rates
of
in
patients
newly
diagnosed
compare
it
according
microsatellite
status.
Methods
The
was
a
single-center
case-control
study.
Patients
at
least
three
months
after
last
vaccine
(BNT162b2,
CoronaVac)
dose
were
included.
dMMR
stable
(MSS)
tumors
defined
as
cases
controls,
respectively,
between
June
2021
2023.
Baseline
characteristics
status
groups
compared
univariable
multivariable.
Inflammation
markers
MSS+CoronaVac
dMMR+BNT162b2
groups.
Results
A
total
76
BMI
higher
MSS
group
(BMI>25
84.3%
vs.
57.9%,
p=0.00),
right-sided
more
common
(71%
vs.46.4%,
p=0.00).
had
BNT162b2
history
than
(86.8%
63.2%,
p=0.01),
while
there
no
difference
CoronaVac
(p=0.32).
Significant
variables
analysis
(BMI,
localization,
BNT162b2)
included
multivariable
logistic
regression.
significantly
(OR:
6.39,
95%
CI:
1.55-26.26,
p=0.01).
median
C-reactive
protein
(CRP)
level
(p=0.01),
erythrocyte
sedimentation
rate
(p=0.05),
lower
lymphocyte/CRP
ratio
(p=0.04)
group.
Conclusion
Immune
infiltration
may
interact
vaccine-induced
activation.
Long-term
clinical
preclinical
studies
are
needed
confirm
these
findings.
Current Topics in Medicinal Chemistry,
Год журнала:
2023,
Номер
23(27), С. 2552 - 2589
Опубликована: Авг. 25, 2023
Vaccines
are
instrumental
tools
to
fight
against
novel
and
re-emerging
pathogens
curb
pandemics.
Vaccination
has
been
an
integral
part
of
the
multifaceted
public
health
response
COVID-19
pandemic.
Diverse
vaccine
platforms
have
designed
currently
at
different
stages
development.
Some
vaccines
still
in
early
biological
testing,
while
others
launched
after
being
approved
by
regulatory
agencies
worldwide.
Genomic
that
deliver
parts
viral
DNA
or
RNA
host
cells
gained
popularity
recently
due
their
high
efficiency
fast
manufacture.
Furthermore,
recent
clinical
studies
encouraged
use
within
primary
vaccination
course
enhance
efficacy
vaccination.
Herein,
we
discuss
genomic
vaccines,
which
genetic
material
through
diverse
biotechnology
platforms,
including
vector
messenger
nucleic
acid
vaccines.
We
compare
contrast
characteristics,
composition,
pros
cons
among
as
well
non-genomic
This
review
summarizes
all
current
knowledge
about
could
be
highly
valuable
researchers
interested
